ACET Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Adicet Bio, Inc.'s net margin of --. Adicet Bio, Inc.'s return on equity of -71.7% beat CEL-SCI Corp.'s return on equity of -266.61%.

Adicet Bio, Inc. has a consensus price target of $7.17, signalling upside risk potential of 1351.63%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that Adicet Bio, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Adicet Bio, Inc. is more attractive than CEL-SCI Corp..

Adicet Bio, Inc. has a beta of 1.610, which suggesting that the stock is 60.995% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Adicet Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adicet Bio, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Adicet Bio, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Adicet Bio, Inc.'s net income of -$26.9M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Adicet Bio, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adicet Bio, Inc. is 1.50x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

EXACT Sciences Corp. has a net margin of -- compared to Adicet Bio, Inc.'s net margin of -2.3%. Adicet Bio, Inc.'s return on equity of -71.7% beat EXACT Sciences Corp.'s return on equity of -38%.

Adicet Bio, Inc. has a consensus price target of $7.17, signalling upside risk potential of 1351.63%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $104.56 which suggests that it could grow by 2.69%. Given that Adicet Bio, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Adicet Bio, Inc. is more attractive than EXACT Sciences Corp..

Adicet Bio, Inc. has a beta of 1.610, which suggesting that the stock is 60.995% more volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.

Adicet Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adicet Bio, Inc. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.

Adicet Bio, Inc. quarterly revenues are --, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Adicet Bio, Inc.'s net income of -$26.9M is lower than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Adicet Bio, Inc.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adicet Bio, Inc. is 1.50x versus 6.20x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Adicet Bio, Inc.'s net margin of -953.4%. Adicet Bio, Inc.'s return on equity of -71.7% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Adicet Bio, Inc. has a consensus price target of $7.17, signalling upside risk potential of 1351.63%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that Adicet Bio, Inc. has higher upside potential than IGC Pharma, Inc., analysts believe Adicet Bio, Inc. is more attractive than IGC Pharma, Inc..

Adicet Bio, Inc. has a beta of 1.610, which suggesting that the stock is 60.995% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Adicet Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adicet Bio, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Adicet Bio, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Adicet Bio, Inc.'s net income of -$26.9M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Adicet Bio, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adicet Bio, Inc. is 1.50x versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MaxCyte, Inc. has a net margin of -- compared to Adicet Bio, Inc.'s net margin of -181.81%. Adicet Bio, Inc.'s return on equity of -71.7% beat MaxCyte, Inc.'s return on equity of -23.05%.

Adicet Bio, Inc. has a consensus price target of $7.17, signalling upside risk potential of 1351.63%. On the other hand MaxCyte, Inc. has an analysts' consensus of $6.68 which suggests that it could grow by 345.33%. Given that Adicet Bio, Inc. has higher upside potential than MaxCyte, Inc., analysts believe Adicet Bio, Inc. is more attractive than MaxCyte, Inc..

Adicet Bio, Inc. has a beta of 1.610, which suggesting that the stock is 60.995% more volatile than S&P 500. In comparison MaxCyte, Inc. has a beta of 0.310, suggesting its less volatile than the S&P 500 by 69.039%.

Adicet Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MaxCyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adicet Bio, Inc. pays -- of its earnings as a dividend. MaxCyte, Inc. pays out -- of its earnings as a dividend.

Adicet Bio, Inc. quarterly revenues are --, which are smaller than MaxCyte, Inc. quarterly revenues of $6.8M. Adicet Bio, Inc.'s net income of -$26.9M is lower than MaxCyte, Inc.'s net income of -$12.4M. Notably, Adicet Bio, Inc.'s price-to-earnings ratio is -- while MaxCyte, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adicet Bio, Inc. is 1.50x versus 4.63x for MaxCyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.